The Inhalation Capsules Market is Predict to reach USD 1.4 Billion by 2031, at a CAGR of 5.9%

19-Apr-2024 | Report Format: Electronic (PDF)

Inhalation Capsules Market Growth, Trends and Report Highlights

According to a new report, published by KBV research, The Global Inhalation Capsules Market size is expected to reach $1.4 billion by 2031, rising at a market growth of 5.9% CAGR during the forecast period.

Emerging technological advancements, the rising prevalence of respiratory conditions, the expanding demand for practical drug delivery methods, and the increasing adoption of inhalation therapies have all contributed to the substantial growth of the inhalation capsules market in recent years. Moreover, the convenience and portability offered by inhalation capsules are driving their adoption among patients and healthcare professionals. DPIs are compact, easy to use, and do not require fuel or coordination of breath, making them suitable for use across diverse patient populations, including children and the elderly. This ease of use enhances patient compliance and reduces the likelihood of medication errors, thereby improving treatment outcomes.

Inhalation Capsules Market Size - By Region

The Gelatin Capsules segment is leading the Global Inhalation Capsules Market by Type in 2023 thereby, achieving a market value of $823.7 Million by 2031. The gelatin capsules are specifically engineered to withstand the rigors of handling and inhalation while ensuring efficient delivery of dry powder medications into the lungs. Gelatin capsules are easy to handle and load into inhalation devices, making them convenient for patients. Moreover, some patients prefer gelatin capsules over other inhalation devices due to taste, ease of use, and perceived efficacy. This, in turn, is driving the growth of the segment.

The COPD Management segment is anticipated to have a CAGR of 6.1% during (2024 - 2031). In regions with substantial levels of air pollution and smoking, where the global prevalence of COPD is increasing, there is a greater demand for effective COPD management options, such as inhalation medications. As a result of their efficacy in reducing inflammation and facilitating bronchodilation, inhalation medications are exceptionally useful in the management of COPD symptoms. This results in enhanced lung function and an improved quality of life for affected individuals.

Full Report: https://www.kbvresearch.com/inhalation-capsules-market/

The North America region dominated the Global Inhalation Capsules Market by Region in 2023 and would continue to be a dominant market till 2031; thereby, achieving a market value of $464.4 Million by 2031. The Europe region is experiencing a CAGR of 5.5% during (2024 - 2031). Additionally, The Asia Pacific region would exhibit a CAGR of 6.7% during (2024 - 2031).

List of Key Companies Profiled

  • Cipla Limited
  • Novartis AG
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Lonza Group Ltd. (Capsugel)
  • Chiesi Farmaceutici S.p.A
  • Vectura Group Plc (Philip Morris International, Inc.)
  • Elpen S.A.
  • Healthcaps India Ltd.
  • Qualicaps Co., LTD. (Roquette Freres SA)

Inhalation Capsules Market Report Segmentation

By Type

  • Gelatin Capsules
  • Hypromellose Capsules

By Application

  • Asthma Treatment
  • COPD Management
  • Others

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

SPECIAL PRICING & DISCOUNTS


  • Buy Sections of This Report
  • Buy Country Level Reports
  • Request for Historical Data
  • Discounts Available for Start-Ups & Universities
HAVE A QUESTION?

HAVE A QUESTION?

Call: +1(646) 600-5072

Unique Offerings Unique Offerings


  • Exhaustive coverage
  • The highest number of Market tables and figures
  • Subscription-based model available
  • Guaranteed best price
  • Support with 10% customization free after sale